Leerink Partnrs Has Negative Outlook for Geron Q2 Earnings

Geron Co. (NASDAQ:GERN) – Stock analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for Geron in a research note issued on Monday, January 6th. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical company will post earnings per share of $0.00 for the quarter, down from their previous forecast of $0.01. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron’s Q3 2025 earnings at $0.01 EPS and Q4 2025 earnings at $0.02 EPS.

Several other brokerages also recently weighed in on GERN. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Geron in a research note on Tuesday, December 10th. Barclays raised shares of Geron to a “strong-buy” rating in a research note on Friday, November 29th. Scotiabank assumed coverage on Geron in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Geron in a report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.15.

Geron Trading Up 0.6 %

NASDAQ:GERN opened at $3.42 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The firm has a 50-day simple moving average of $3.84 and a 200-day simple moving average of $4.24. Geron has a one year low of $1.64 and a one year high of $5.34. The firm has a market cap of $2.07 billion, a P/E ratio of -10.69 and a beta of 0.55.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. The company had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The firm’s revenue for the quarter was up 17138.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.08) EPS.

Institutional Investors Weigh In On Geron

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its holdings in Geron by 26.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,016,622 shares of the biopharmaceutical company’s stock valued at $8,550,000 after buying an additional 415,883 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Geron by 4.2% in the second quarter. Commonwealth Equity Services LLC now owns 262,324 shares of the biopharmaceutical company’s stock valued at $1,112,000 after purchasing an additional 10,608 shares during the period. CIBC Asset Management Inc grew its holdings in shares of Geron by 32.7% in the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 3,805 shares during the period. Rhumbline Advisers increased its position in Geron by 16.4% during the second quarter. Rhumbline Advisers now owns 846,768 shares of the biopharmaceutical company’s stock worth $3,590,000 after purchasing an additional 119,550 shares during the last quarter. Finally, TD Asset Management Inc raised its stake in Geron by 403.0% during the second quarter. TD Asset Management Inc now owns 1,201,200 shares of the biopharmaceutical company’s stock worth $5,093,000 after purchasing an additional 962,400 shares during the period. Institutional investors and hedge funds own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.